Results of Intravitreal Bevacizumab in Macular Edema Secondary to Central and Branch Retinal Vein Occlusion

1. Dr Kashif Iqbal
2. Dr Tariq Khan
3. Dr Khurram Mirza
4. Dr Z A Qazi
5. Dr Hanan Jamil
6. Dr Ahmad Zeshan

LRBT Eye Hospital, Lahore, Pakistan

Purpose: Results of Intravitreal Bevacizumab in Macular Edema Secondary to Central and Branch Retinal Vein Occlusion

Methods:In a study we analysed anatomic and functional outcomes from series of 45
eyes of 45 patients with branch retinal vein occlusion (BRVO) and a second cohort of 56 eyes with central retinal vein occlusion (CRVO). Bevacizumab was administered at an intravitreal dose of 1.25 mg in all patients and they were followed monthly with evaluations that included BCVA and optical coherence tomography (OCT). Further injections were given based on changes in those parameters. All eyes had a minimum follow-up of six months after the first bevacizumab injection

Results: At last follow-up, all BRVO eyes were within three lines of baseline BCVA and
two-thirds benefited with a gain of at least three lines. Among the CRVO eyes, BCVA improved by two or more lines in 60 per cent and remained within one line in 32.5 per cent, while 7.5 per cent lost two or more lines. In both groups mean central macular thickness calculated on OCT was significantly reduced from baseline

Conclusion: In both the group of eyes with BRVO and those with CRVO, BCVA and central
macular thickness improved significantly from baseline by the first follow-up at one month. Thereafter, the effects were maintained in the CRVO eyes while as a group, the BRVO eyes showed further improvements during continued follow-up and achieved better overall outcomes (in terms of BCVA and macular thickness) compared with the CRVO eyes.